Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene

Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene

Colorectal cancer (CRC) is the third most common cancer in terms of incidence rate in adults and the second most common cause of cancer-related death in Europe. The treatment of metastatic CRC (mCRC) is based on the use of chemotherapy, anti-vascular endothelial growth factor (VEGF), and anti-epider...

Full description

Bibliographic Details
Main Authors: Javier Torres-Jiménez, Jorge Esteban-Villarrubia, Reyes Ferreiro-Monteagudo
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Cancers
Subjects:
colorectal cancer
precision medicine
ERBB2
HER-2
Online Access:https://www.mdpi.com/2072-6694/14/15/3718

Similar Items

Similar Items